As there are no known cellular mechanisms to fully suppress BC development in vivo [1], clinical cases are treated with selective estrogen receptor modulators (SERMs, mixed agonists/antagonists of ERα), and selective ERα down-regulators (SERDs, full antagonists of ERα). This evidence concerns the gene ERAS and breast cancer.